1.   Evista, known chemically as raloxifene, is part of a new class of drugs known as selective estrogen receptor modulators.

2.   Lilly is the first company to win approval for a so-called selective estrogen receptor modulator for osteoporosis prevention.

3.   Raloxifene is one known as a SERM for selective estrogen receptor modulator.

4.   Raloxifene, developed by Lilly under the name Evista, belongs to a new class of drugs called selective estrogen receptor modulators, or SERMS.

5.   Tamoxifen and raloxifene belong to a class of drugs called SERMS, for selective estrogen receptor modulators.